Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden
Evolent Health (NYSE: EVH) and American Oncology Network announced a national partnership on Nov 6, 2025 to deploy a quality‑focused cancer care model that aims to reduce costs, speed treatment and remove prior authorization for providers who meet quality standards.
Key elements include gold‑carding providers who adhere to treatment pathways (eliminating most prior authorizations), an AI analytics platform called MiBA for personalized treatment insights, an aligned payment model to reward high‑quality care, and Evolent's care navigation program, Careology. The model will roll out in select markets in the year ahead.
Evolent Health (NYSE: EVH) e American Oncology Network hanno annunciato una partnership nazionale il 6 novembre 2025 per implementare un modello di assistenza oncologica orientato alla qualità che mira a ridurre i costi, accelerare i trattamenti e rimuovere l'autorizzazione preventiva per i fornitori che rispettano gli standard di qualità.
Elementi chiave includono fornitori gold-carding che aderiscono ai percorsi di trattamento (eliminando la maggior parte delle autorizzazioni preventive), una piattaforma di analisi AI chiamata MiBA per insights personalizzati sui trattamenti, un modello di pagamento allineato per premiare la cura di alta qualità e il programma di navigazione delle cure di Evolent, Careology. Il modello sarà implementato in mercati selezionati nel prossimo anno.
Evolent Health (NYSE: EVH) y American Oncology Network anunciaron una asociación nacional el 6 de noviembre de 2025 para implementar un modelo de atención oncológica centrado en la calidad que busca reducir costos, acelerar el tratamiento y eliminar la autorización previa para los proveedores que cumplan con estándares de calidad.
Los elementos clave incluyen proveedores gold-carding que se adhieren a rutas de tratamiento (eliminando la mayoría de las autorizaciones previas), una plataforma de analítica de IA llamada MiBA para obtener insights personalizados sobre el tratamiento, un modelo de pago alineado para recompensar una atención de alta calidad y el programa de navegación de cuidados de Evolent, Careology. El modelo se implementará en mercados selectos durante el próximo año.
Evolent Health (NYSE: EVH)와 American Oncology Network는 2025년 11월 6일 전국 파트너십을 발표했습니다. 질 관리에 초점을 둔 암 치료 모델을 도입하여 비용을 절감하고 치료를 가속화하며 품질 기준을 충족하는 공급자에 대한 사전 승인(pre-authorization)을 제거하는 것을 목표로 합니다.
핵심 요소로는 치료 경로를 준수하는 골드카딩 공급자(대부분의 사전 승인을 제거), 치료에 대한 개인화된 통찰을 제공하는 AI 분석 플랫폼 MiBA, 고품질 치료에 보상을 주기 위한 정렬된 지불 모델, Evolent의 치료 탐색 프로그램인 Careology가 있습니다. 이 모델은 향후 1년 동안 선택된 시장에서 점진적으로 도입될 예정입니다.
Evolent Health (NYSE: EVH) et American Oncology Network ont annoncé un partenariat national le 6 novembre 2025 afin de déployer un modèle de soins oncologiques axé sur la qualité qui vise à réduire les coûts, accélérer les traitements et supprimer l'autorisation préalable pour les prestataires qui respectent les standards de qualité.
Les éléments clés incluent des prestataires gold-carding qui adhèrent à des parcours de traitement (éliminant la majeure partie des autorisations préalables), une plateforme d'analyse IA appelée MiBA pour des insights personnalisés sur les traitements, un modèle de paiement aligné pour récompenser des soins de haute qualité et le programme de navigation des soins d'Evolent, Careology. Le modèle sera déployé sur des marchés sélectionnés au cours de l'année à venir.
Evolent Health (NYSE: EVH) und American Oncology Network haben am 6. November 2025 eine landesweite Partnerschaft bekannt gegeben, um ein qualitätsorientiertes Krebsbehandlungsmodell einzuführen, das darauf abzielt, Kosten zu senken, die Behandlung zu beschleunigen und die Vorabgenehmigung für Anbieter zu entfernen, die Qualitätsstandards erfüllen.
Zu den Schlüsselelementen gehören Gold-Carding-Anbieter, die sich an Behandlungswege halten (die meisten Vorabgenehmigungen entfallen), eine KI-Analytik-Plattform namens MiBA für personalisierte Behandlungseinblicke, ein auf hochwertige Versorgung ausgerichtetes Zahlungsmodell und Evolents Pflege-Navigationsprogramm Careology. Das Modell wird im kommenden Jahr schrittweise in ausgewählten Märkten eingeführt.
Evolent Health (NYSE: EVH) و American Oncology Network أعلنا شراكة وطنية في 6 نوفمبر 2025 لتبنّي نموذج رعاية سرطانية يركّز على الجودة يهدف إلى خفض التكاليف، تسريع العلاج، وإزالة التفويض المسبق للمقدّمين الذين يستوفون معايير الجودة.
تشمل العناصر الرئيسية الاعتماد الذهبي للمقدّمين الذين يلتزمون بمسارات العلاج (إلغاء معظم الموافقات المسبقة)، منصة تحليلات AI تسمّى MiBA للحصول على رؤى مخصّصة للعلاج، ونموذج دفع مواءم لمكافأة الرعاية عالية الجودة وبرنامج التنقل في الرعاية التابع لـ Evolent، Careology. سيطرح النموذج في أسواق مختارة في العام المقبل.
- Prior authorization removed for most tests and treatments for gold‑carded providers
- MiBA AI analytics platform delivers evidence‑based, personalized treatment insights
- Evolent Careology navigation added to AON to support patient management
- Developing an aligned payment model to reward high‑quality oncology care
- Rollout limited to select markets in the year ahead, limiting near‑term scale
- Gold‑carding requires provider adherence to quality pathways to access benefits
- No payer commitments or financial terms disclosed for broader authorization removal
Insights
Partnership targets prior‑authorization removal, payment alignment, and AI insights to reduce administrative burden and speed oncology care.
Evolent and American Oncology Network (AON) combine quality pathways, an AI analytics platform (MiBA), and a care navigation program to change how community oncology is delivered and paid. The model links provider performance to operational relief by "gold‑carding" adherent clinicians so they no longer need prior authorization for most tests and treatments, while embedding automated reminders, scorecards, and incentives into workflows.
Key dependencies and risks include the exact scope of prior‑authorization exemptions, the measured quality metrics that trigger "gold‑card" status, and the real‑world performance of MiBA in delivering actionable, EHR‑integrated insights. Implementation also depends on payer participation in the aligned payment model and on whether incentives materially shift regimen selection toward the stated quality goals.
Concrete items to watch in the near term are the rollout in select markets in
The national partnership seeks to improve clinical decision-making by introducing quality-focused interventions, driving clinical insights through an innovative data and analytics platform, and rewarding providers for high-quality care. As providers demonstrate adherence to quality, they will be "gold-carded" — no longer required to seek authorization from payers for most tests and treatments. Meanwhile, Evolent intends to use its care navigation program to complement AON's existing capabilities to help patients manage daily life with cancer and stay better connected to their oncology team. AON and Evolent expect to roll out this model in select markets in the year ahead.
"Community oncology practices are a linchpin of our cancer care system, but they face immense pressures, from administrative burdens and financial stresses to care coordination needs," said AON Chief Medical Officer Dr. Stephen "Fred" Divers. "With its provider-centric approach and uncompromising focus on doing what is best for patients, Evolent is an ideal partner. Evolent's quality efforts go beyond common strategies that are largely tapped out — like shifting to biosimilars — to tackle some of the major drivers of quality and costs in cancer care."
Key components of the program include:
- Quality initiatives. Evolent and AON will help providers act on high-impact but underused opportunities to improve quality and affordability across the full continuum of care beyond traditional utilization management. The partnership seeks to drive sustained quality improvement through a systematic approach that combines provider education, scorecards, automated reminders delivered directly in the electronic medical record, and incentives.
- AI-driven clinical insights. The model is powered in part by MiBA (Meaningful Insights Biotech Analytics), an innovative data and analytics platform co-developed in collaboration with AON, that supports providers with evidence-based insights and personalized cancer treatment plans. Harnessing real-time data in the electronic health record, the platform uses analytics and algorithms to uncover patterns, trends and correlations that can improve patient care and drive innovation.
- Payment innovation. AON and Evolent are developing an aligned payment model seeking to reward oncology practices for delivering high-quality care. Moving beyond traditional fee-for-service models, the model aims to re-wire incentives to encourage providers to select the clinically optimal drug regimen for each patient.
- Eliminating prior authorization. Providers who adhere to high-quality treatment pathways will no longer need prior authorization for most tests and treatments. This should accelerate the time to treatment and reduce the administrative burden for practices and patients.
- Care navigation. AON patients will have access to Evolent's comprehensive cancer care navigation program, which combines personalized navigation and a cancer care management platform, Careology, to help patients move through their journey with greater confidence and support. AON and Evolent believe this program will bolster AON's existing care management capabilities and support the goal of end-to-end condition management.
"Patients, providers and health plans want the same thing out of the cancer journey — longer survival and a higher quality of life without unnecessary costs or hassles," said Evolent President Dan McCarthy. "Yet, traditional models create friction between these groups as well as gaps, resulting in misaligned care, provider burnout and administrative waste. We're thrilled to collaborate with American Oncology Network, as another leader in high-value cancer care, to create an ecosystem in which everyone wins when patients receive the best possible care."
About Evolent
Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.
About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON's rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.
Media inquiries
Evolent
Jamie Manfuso
media@evolent.com
American Oncology Network
Karen Riley Sawyer
Karen.Sawyer@AONcology.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-and-american-oncology-network-unveil-innovative-model-seeking-to-improve-cancer-care-while-eliminating-prior-authorization-burden-302607605.html
SOURCE Evolent Health, Inc.
FAQ
What did Evolent (EVH) and American Oncology Network announce on November 6, 2025?
How does the new model affect prior authorization for EVH and AON providers?
What is MiBA and how will it support oncology care under the EVH–AON model?
When will Evolent and AON roll out the new cancer care model?
Will Evolent's Careology navigation be available to American Oncology Network patients?
